Home     Log in

Archive for July 3rd, 2008

PSA - A Controversial but Useful Test

July 3rd, 2008 by admin | No Comments | Filed in Uncategorized

With the advent of the PSA (Prostate Specific Antigen) blood test two decades ago, the screening for and detecting of in the United States has been revolutionized.

Introduction

PSA is a protein manufactured in the prostate. There is an association between the PSA level and the likelihood of the man having .

Previously, the only screening test for was a digital rectal exam. That meant a physician inserted his or her gloved finger into the man’s rectum to determine if he or she felt any lumps or bumps in the prostate gland. By that point, the cancer was relatively far advanced. Fortunately, PSA blood tests can detect a prostate malignancy at a much earlier stage. This is known as a stage shift.

When is a PSA level elevation significant?

As men age, they often develop a non-cancerous increase in the size of the prostate, known as benign prostatic hyperplasia. This also elevates PSA, which leads to controversy as to whether or not to send the man for a prostate biopsy. The latter is an invasive procedure, but it is the method by which is diagnosed.

Over the last twenty years, much research took place to determine what constitutes a normal PSA level. In the ’80s and ’90s, physicians used a cutoff of a value of 4. However, doctors now know that there is really no “normal” level of PSA. Instead, there are ranges and trends of PSA. Generally, the current acceptable cutoff is 2.5, so any level above 2.5 is considered an abnormal PSA.

The normal level of PSA changes over a man’s lifetime. As previously stated, as a man ages, the prostate gland’s volume increases. Thus, the actual cut off point of normal PSA level changes as a function of age.

For men in their 70s, one might accept a level of 2.5 because the likelihood of that person’s elevation of PSA being a consequence of benign prostatic hyperplasia is much greater than his likelihood of having . For younger men, it might be worrisome when the PSA rises to 2.5.

PSA level trends

Physicians are also interested in how the PSA level changes over time. For example, a PSA that rose gradually over many years, even if the level itself were over 4, is much less concerning than a number that jumped from 2 to 4 in one year. The rate change of PSA over time is known as the PSA velocity. Also, PSA doubling time is the time it takes for the PSA to go from some level to twice that level.

In a man with , the shorter the PSA doubling time is, the greater the rate of growth of the disease. This is a prognosticator and it suggests the need for medical intervention instead of observation.

PSA level to monitor the activity of

Treatment for early stage is usually local therapy, namely surgery or radiation therapy. When the prostate is removed, PSA levels normally drop to zero. When radiation is used, there may still be some detectable PSA, but at very low levels.

After surgery or radiation, physicians generally check the PSA every three months for a few years. When the PSA level remains stable over time, the likelihood is strong that the person has been cured. Thereafter, doctors can decrease the interval of checking the PSA.

Ongoing measurements of PSA are an important means to follow a person with a history of . While there is controversy about using PSA as a screening tool in the general population, there is none about the value of PSA as a monitoring tool in someone who has been treated for .

When the PSA level climbs over several sequential measurements, it is considered to represent what is called a biochemical failure, PSA-detectable disease, or PSA recurrence. How to manage a PSA recurrence varies from one patient to the next. Certainly, there are men who have a rising PSA after local therapy who will never have any problem with recurrent cancer.

However, there are people who will develop a cancer recurrence, characterized by a rapidly rising PSA before they have detectable cancer on a scan. Aggressive treatments can make a difference in the lives of these men.

Treatment for PSA recurrence

Currently available treatments include the use of hormonal or androgen-deprivation therapy, to prevent the production or action of the male hormone testosterone on cells. This can be achieved via the surgical removal of the testicles, or, more commonly, through the use of hormonal medications.

Unfortunately, hormonal treatments often fail after a period of time, and rising PSA levels may be the first indication. If the PSA is rising, it signifies what is called hormone-refractory . Nonetheless, in this late stage of disease, further treatment is still available.

Over the past year or two, more studies have proven the benefit of in advanced . Not only does prolong life in men with hormone-refractory , but it can also improve their quality of life.

Conclusions

While debate remains about the best use of PSA testing in the population at large, especially for screening, experts agree that PSA and its relationship to has had a significant effect on making treatment decisions for a disease that affects a many men.

Dr. Kornmehl is a board certified radiation oncologist at Passaic Beth Israel Medical Center and author of the critically acclaimed consumer health book, “The Best News About Radiation Therapy” (M. Evans, 2004). Her website is RTSupportDoc.com RTSupportDoc.com.

Tags: ,

Related posts

Tags: ,

Adverse Effects of Breast Cancer Chemotherapy

July 3rd, 2008 by admin | No Comments | Filed in Uncategorized

Undergoing for patients will definitely increase overall survival; the occurrence of adverse events is inevitable. Of all the side effects of , bone marrow toxicity. The bone marrow primarily functions as the production site of white and red blood cells. Most women treated with for will experience a decline in their white blood cell count, most often seven to fourteen days after treatment. This drop of cell count is known as leucopenia. Thus, while on , the patient should be alert for any infection, which is the first sign of bone marrow suppression. The most immediate symptom of an infection will be a fever.

As a , it is important that you alert your physician at the first signs of infection and to receive antibiotic therapy. There are some clinical protocols that routinely put women on antibiotics the second week after each session as a prophylactic measure against infection. Gene technology is now trying to get into the picture of safer . There are genetically engineered bone marrow stimulants available for women who develop severe depression of their white or red blood cell counts. Drugs like Neuprogen and Epogen are some of these agents. Fortunately, the toxicity to the bone marrow that occurs after is temporary and reversible. If an infection occurs, it is potentially very serious and must be addressed immediately to avoid fatal complications.

Also showing sensitivity to anticancer drugs are the cells that line the gastrointestinal tract from the mouth to the anus, which undergo cell division regularly and which the body manufactures and replaces every few days. Some anticancer drugs interrupt this production of cells, causing small ulcers. Fortunately, this is quite unusual in , but can still occur. The mouth and the rectal areas are the most susceptible.

The most common gastrointestinal symptom of cancer is nausea and vomiting, most often during the week immediately following treatment. This is primarily due to a massive mediator release of substances called histamines, which are stored in the cells lining the gastrointestinal tract. New drugs can now prevent the release of histamines for patients undergoing . Since the discover and appropriate use of supportive medications, the nausea and vomiting accompanying is much less of a problem than it used to be. The incidence of these adverse events varies depending on the drugs used and the dose intensity with which they are used.

For most women, hair loss (alopecia) is a very distressing side effect of a few anticancer agents. Some of the agents such as doxorubicin, paclitaxel, docetaxel can cause uniform temporary alopecia, especially from the scalp. Other drugs only cause minimal hair thinning. Many of the regimens have doxorubicin and some of the newer ones have paclitaxel or docetaxel, so temporary hair loss should be anticipated after undergoing .

Because side effects can be debilitating, many women want to know if they can continue to work while on . The answer varies depending on the regimen used and the stress and demands of the particular job. Whether the patient decides to continue working or not, it is important that during the several months of , she should plan to take it easy - reduce as much stress as she can. She should engage herself with loved ones, friends and extend support system especially during the periods when she is down and not feeling well.

Michael Russell
Your Independent guide to breast-cancer.treatment-and-guides.com/ Breast Cancer

Tags: , ,

Related posts

Tags: , ,

Mesothelioma Litigation: An Overview

July 3rd, 2008 by admin | No Comments | Filed in Uncategorized

Mesothelioma is a deadly and rare form of cancer that develops from exposure to asbestos. The inhaling of the highly toxic asbestos is the major reason of the . The ingested particle of the asbestos develops the cancerous or the malignant cells in the mesothelium. The mesothelium is the cell structure that covers and surrounds various internal organs.

The person who has developed through exposure to asbestos can seek the legal assistance for the compensation. Mesothelioma litigation has developed in large numbers. This is because some companies allow employees to work with asbestos - the cause for this deadliest disease - without informing the workers. For the wrongful deaths of the people who have developed by these irresponsible firms, claims can be filed for legal compensation for the sufferer or for the benefit of the family. This is referred to as litigation.

Low levels of protection and the lack of effort to control the exposure of humans to asbestos has developed litigation, inciting damage. The unawareness of the workers of the asbestos exposure causes them to delay the necessary medical treatment. The treatment of is very expensive. One cannot pay for it in at their own expense. The person who has developed through exposure to asbestos can seek immediate legal assistance for maximum compensation.

A lawyer who has a good track record in dealing with these cases can help you in receiving the compensation money from the irresponsible asbestos-related companies. The compensation for the victims who have developed with the exposure of asbestos can be awarded millions of dollars as the payout. Mesothelioma litigation helps the person who has developed to receive a good and fair compensation amount from the firms that expose the asbestos. The money is intended for the fulfillment of basic needs, medical expenses, personal loss, and damages that happened due to the .

e-mesotheliomalitigation.com Mesothelioma Litigation provides detailed information on History of Mesothelioma Litigation, Mesothelioma Diagnosis: A Guide, Mesothelioma Laws, Mesothelioma Lawyers: A Guide and more. Mesothelioma Litigation is affiliated with e-californiacontractorlicenses.com California Contractor License Bond.

Tags:

Related posts

Tags:

What You Should Know About Breast Cancer

July 3rd, 2008 by admin | No Comments | Filed in Uncategorized

Breast cancer is the most common malignancy in women and the second leading cause of cancer death, exceeded only by in 1985. One woman in eight who lives to age 85 will develop at some time during her life.

At present there are over 2 million women living in the United States who have been treated for . About 41,000 women will die from the disease. The chance of dying from is about 1 in 33. However, the rate of death from is going down. This decline is probably the result of early detection and improved treatment.

Breast cancer is not just a woman’s disease. The American Cancer Society estimates that 1600 men develop the disease yearly and about 400 may die from the disease.

Breast is higher among those who have a mother, aunt, sister, or grandmother who had before age 50. If only a mother or sister had , your risk doubles. Having two first-degree relatives who were diagnosed increases your risk up to five times the average.

Although it is not known exactly what causes ; sometimes the culprit is a hereditary mutation in one of two genes, called BRCA1 and BRCA2. These genes normally protect against the disease by producing proteins that guard against abnormal cell growth, but for women with the mutation, the lifetime risk of developing can increase up to 80 percent, compared with 13 percent among the general population. In effect, more than 25 percent of women with have a family history of the disease.

For women without a family history of , the risks are harder to identify. It is known that the hormone estrogen feeds many breast cancers, and several factors – diet, excess weight, and alcohol consumption – can raise the body’s estrogen levels.

Early Signs

Early signs of include the following:

- A lump which is usually single, firm and most often painless is detected.

- An area of the skin on the breast or underarm is swollen and has an unusual appearance.

- Veins on the skin surface become more prominent on one breast.

- The affected breast nipple becomes inverted, develops a rash, changes in skin texture, or has a discharge other than breast milk.

- A depression is found in an area of the breast surface.

Types and Stages of Breast Cancer

There are many different varieties of . Some are fast-growing and unpredictable, while others develop more slowly and steady. Some are stimulated by estrogen levels in the body; some result from mutation in one of the two previously mentioned genes - BRCA1 and BRCA2.

Ductal Carcinoma In-Situ (DCIS): Generally divided into comedo (blackhead), in which the cut surface of the tumor shows extrusion of dead and necrotic tumor cells similar to a blackhead, and non-comedo types. DCIS is early that is confined to the inside of the ductal system. The distinction between comedo and non-comedo types is important, as comedocarcinoma in-situ generally behaves more aggressively and may show areas of micro-invasion through the ductal wall into surrounding tissue.

Infiltrating Ductal: This is the most common type of , representing 78 percent of all malignancies. On mammography, these lesions can appear in two different shapes — stellate (star- like) or well circumscribed (rounded). The stellate lesions generally have a poorer prognosis.

Medullary Carcinoma: This malignancy comprises 15 percent of breast cancers. These lesions are generally well circumscribed and may be difficult to distinguish from fibroadenoma by mammography or sonography. With this type of , prognostic indicators estrogen and progesterone receptor are negative 90 percent of the time. Medullary carcinoma usually has a better prognosis than other types of .

Infiltrating Lobular: Representing 15 percent of breast cancers, these lesions generally appear in the upper outer quadrant of the breast as a subtle thickening and are difficult to diagnose by mammography. Infiltrating lobular can involve both breasts (bilateral). Microscopically, these tumors exhibit a linear array of cells and grow around the ducts and lobules.

Tubular Carcinoma: This is described as orderly or well-differentiated carcinoma of the breast. These lesions make up about 2 percent of breast cancers. They have a favorable prognosis with nearly a 95 percent 10-year survival rate.

Mucinous Carcinoma: Represents 1-2 percent of carcinoma of the breast and has a favorable prognosis. These lesions are usually well circumscribed (rounded).

Inflammatory Breast Cancer: This is a particularly aggressive type of that is usually evidenced by changes in the skin of the breast including redness (erythema), thickening of the skin and prominence of the hair follicles resembling an orange peel. The diagnosis is made by a skin biopsy, which reveals tumors in the lymphatic and vascular channels about 50 percent of the time.

Stages of Breast Cancer

The most common type of is ductal carcinoma. It begins in the lining of the ducts. Another type, called lobular carcinoma, arises in the lobules. When cancer is found, the pathologist can tell what kind of cancer it is - whether it began in a duct (ductal) or a lobule (lobular) and whether it has invaded nearby tissues in the breast (invasive).

When cancer is found, special lab tests of the tissue are usually done to learn more about the cancer. For example, hormone (estrogen and progesterone) receptor tests can help determine whether hormones help the cancer to grow. If test results show that hormones do affect the growth of the cancer (a positive test result), the cancer is likely to respond to hormonal therapy. This therapy deprives the cancer cells of estrogen.

Other tests are sometimes done to help predict whether the cancer is likely to progress. For example, x-rays and other lab tests are done. Sometimes a sample of breast tissue is checked for a gene, known as the human epidermal growth factor receptor-2 (HER-2 gene) that is associated with a higher risk that the will recur. Special exams of the bones, liver, or lungs are done because may spread to these areas.

A woman’s treatment options depend on a number of factors. These factors include her age and menopausal status; her general health; the size and location of the tumor and the stage of the cancer; the results of lab tests; and the size of her breast. Certain features of the tumor cells, such as whether they depend on hormones to grow are also considered.

In most cases, the most important factor is the stage of the disease. The stage is based on the size of the tumor and whether the cancer has spread. The following are brief descriptions of the stages of and the treatments most often used for each stage. Other treatments may sometimes be appropriate.

Stage 0

Stage 0 is sometimes called non-invasive carcinoma or carcinoma in situ. Lobular carcinoma in situ (LCIS) refers to abnormal cells in the lining of a lobule. These abnormal cells seldom become invasive cancer. However, they are an indicator of an increased risk of developing in both breasts. The treatment for LCIS is a drug called tamoxifen, which can reduce the risk of developing . A person who is affected may choose not to have treatment, but to monitor the situation by having regular checkups. And occasionally, the decision is made to have surgery to remove both breasts to try to from developing. In most cases, removal of underarm lymph nodes is not necessary.

Ductal carcinoma in situ (DCIS) refers to abnormal cells in the lining of a duct. DCIS is also called intraductal carcinoma. The abnormal cells have not spread beyond the duct to invade the surrounding breast tissue. However, women with DCIS are at an increased risk of getting invasive . Some women with DCIS have breast-sparing surgery followed by radiation therapy. Alternatively, they may choose to have a , with or without breast reconstruction (plastic surgery) to rebuild the breast. Underarm lymph nodes are not usually removed. Also, women with DCIS may want to talk with their doctor about tamoxifen to reduce the risk of developing invasive .

Stage I and II

Stage I and stage II are early stages of in which the cancer has spread beyond the lobe or duct and invaded nearby tissue.

Stage I means that the tumor is about one inch across and cancer cells have not spread beyond the breast.

Stage II means one of the following:

The tumor in the breast is less than 1 inch across and the cancer has spread to the lymph nodes under the arm.
The tumor is between 1 and 2 inches (with or without spread to the lymph nodes under the arm).
The tumor is larger than 2 inches but has not spread to the lymph nodes under the arm.
The treatment options for early stage are breast-sparing surgery followed by radiation therapy to the breast, and , with or without breast reconstruction to rebuild the breast. These approaches are equally effective in treating early stage . (Sometimes radiation therapy is also given after .)

The choice of breast-sparing surgery or depends mostly on the size and location of the tumor, the size of the breast, certain features of the cancer, and how the person feels about preserving the breast. With either approach, lymph nodes under the arm usually are removed.

Chemotherapy and/or hormonal therapy after primary treatment with surgery or surgery and radiation therapy are recommended for stage I and most frequently with stage II . This added treatment is called adjuvant therapy. Systemic therapy sometimes given to shrink the tumor before surgeries called neoadjuvant therapy. This is given to try to destroy any remaining cancer cells and prevent the cancer from recurring, or coming back, in the breast or elsewhere.

Stage III

Stage III is also called locally advanced cancer. In this stage, the tumor in the breast may exhibit the following:

More than 2 inches across and the cancer has spread to the underarm lymph nodes.
The cancer is extensive in the underarm lymph nodes.
The cancer is spreading to lymph nodes near the breastbone or to other tissues near the breast.

Inflammatory is a type of locally advanced . In this type of cancer, the breast looks red and swollen (or inflamed) because cancer cells block the lymph vessels in the skin of the breast.

Patients with stage III usually have both local treatment to remove or destroy the cancer in the breast and systemic treatment to stop the disease from spreading. The local treatment may be surgery and/or radiation therapy to the breast and underarm. The systemic treatment may be , hormonal therapy, or both. Systemic therapy may be given before local therapy to shrink the tumor or afterward to prevent the disease from recurring in the breast or elsewhere.

Stage IV

Stage IV is metastatic cancer. The cancer has spread beyond the breast and underarm lymph nodes to other parts of the body.

The treatments for stage IV are and/or hormonal therapy to destroy cancer cells and control the disease. Patients may have surgery or radiation therapy to control the cancer in the breast. Radiation may also be useful to control tumors in other parts of the body.

Recurrent Cancer

Recurrent cancer means the disease has returned in spite of the initial treatment. Even when a tumor in the breast seems to have been completely removed or destroyed, the disease sometimes returns because undetected cancer cells remained somewhere in the body after treatment.

Most recurrences appear within the first 2 or 3 years after treatment, but can recur many years later.

Cancer that returns only in the area of the surgery is called a local recurrence. If the disease returns in another part of the body, the recurrence is called metastatic . The patient may have one type of treatment or a combination of treatments for recurrent cancer.

For more information, see “Nine Ways to Reduce Breast Cancer Risk” on this site.

Sources: National Cancer Institute; Centers for Disease Control

Syble James is a consultant and author with knowledge of the food, beverage, supplements, MLM, and health and fitness industry. She provides consultations to individual and organizations. She can be reached at Syble.James@AlphaHealthSource.net.

Tags: , , , , ,

Related posts

Tags: , , , , ,